⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EWTX News
Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
prnewswire.com
EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com
EWTX
Form 8-K
sec.gov
EWTX
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
prnewswire.com
EWTX
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
prnewswire.com
EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com
EWTX
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
prnewswire.com
EWTX
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
prnewswire.com
EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com
EWTX
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
prnewswire.com
EWTX